kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
707
JPY
-4
(-0.56%)
Apr 30, 9:00 am JST
4.41
USD
Apr 29, 8:00 pm EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.69
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
707 JPY 4.41 USD
Previous Close Apr 28
711 JPY 4.46 USD
High Apr 30, 9:00 am
707 JPY 4.41 USD
Low Apr 30, 9:00 am
707 JPY 4.41 USD
Volume
1,000
Trading Value
1.00M JPY 4.43K USD
VWAP
707.0 JPY 4.43 USD
Minimum Trading Value
70,700 JPY 441 USD
Market Cap
7.13B JPY 0.04B USD
Number of Trades
2
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
403
1-Year High Oct 1, 2025
6,713
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 929,000
Apr 17, 2026 0 962,300
Apr 10, 2026 0 917,000
Apr 3, 2026 0 905,500
Mar 27, 2026 0 920,800
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.